Who is this course for?
Clinical professionals interested in integrating ketamine-assisted psychotherapy into their practice.
A 16-week course in psychedelic-assisted psychotherapy focused on ketamine-assisted psychotherapy (KAP) for clinical professionals. It combines live online teaching, pre-recorded lectures, and experiential ketamine sessions.
Start date: July 13, 2026
The 16-week Trainings in Psychedelic-Assisted Psychotherapy course offered by the Living Medicine Institute is designed for clinical professionals interested in integrating ketamine-assisted psychotherapy (KAP) into their practice. The course is a blend of didactic learning and experiential sessions, led by some of the most seasoned KAP providers in the country.
Participants will engage in bi-weekly online live teaching sessions that complement a series of pre-recorded video lectures. These didactic components are enriched by seven experiential ketamine sessions, allowing trainees to gain firsthand experience with various routes of ketamine administration. The course is structured to provide both theoretical knowledge and practical skills, without the clinical supervision stage, making it ideal for those who are looking to explore this emerging field but do not yet have an active KAP practice.
The training is conducted in a closed learning container, fostering in-depth understanding and personal exploration. Trainees can attend experiential sessions in Asheville, NC, or at a local clinic that can safely administer ketamine. The course also includes an optional full-day, in-person workshop in Asheville. Homework assignments requiring personal reflection and tracking of learning points are part of the curriculum. Upon completion, participants will have accrued over 5 hours of video lectures, 16 hours of live teaching, and 17+ hours of ketamine experientials, equipping them with the skills and knowledge to begin practice as a KAP therapist.
Clinical professionals interested in integrating ketamine-assisted psychotherapy into their practice.
Intended for clinical professionals; the source notes it is suitable for those without an active KAP practice.
Asheville, North Carolina-based psychedelic therapy training institute founded in 2019 by board-certified psychiatrist Dr. Signi Goldman and licensed psychologist Dr. Sandra Newes, offering concierge-level ketamine-assisted psychotherapy (KAP) training, mentorship, supervision, and community to aspiring psychedelic-assisted therapy clinicians. Living Medicine Institute combines modern neuroscience with ancient healing traditions, provides BIPOC therapist scholarships for underserved communities, and produces the Living Medicine podcast featuring leading psychedelic researchers and clinicians.
View all Living Medicine Institute coursesClinical professionals interested in integrating ketamine-assisted psychotherapy into their practice.
Intended for clinical professionals; the source notes it is suitable for those without an active KAP practice.
Format: Hybrid. Time commitment: 5 hours.
The listed price is $3,200. Confirm the latest tuition, fees, and payment options on the provider website.
The listed next cohort date is 2026-07-13.
The current listing status is Active. Use the provider website for the latest enrollment status.
By Mind Medicine Australia
Shares course skills and categories
Courses tagged with preparation therapy focus on ketamine-assisted psychotherapy and psychedelic-assisted psychotherapy practice. The current catalog includes two offerings from one provider, with formats that combine didactic learning, consultation, supervision, and shadowing.
Next cohort: Dec 1, 2026
By Alma Institute
Shares course skills and categories
Psychedelic-assisted psychotherapy courses covering clinical training, integration, and related therapeutic skills. Listings on this page vary by provider, format, and audience.
Next cohort: Dec 1, 2026
By Alma Institute
Shares course skills and categories
Courses on ketamine-assisted psychotherapy for clinicians and other learners exploring clinical and integration approaches to ketamine use in therapeutic settings.
Next cohort: Dec 1, 2026